CD40-activated B cells can be generated in high number and purity in cancer patients: Analysis of immunogenicity and homing potential

Clinical and Experimental Immunology

Volumn 155, Issue 2, 2009, Pages 249-256

  Kondo, E ^a   Gryschok, L ^a   Klein Gonzalez, N ^a   Rademacher, S ^a   Weihrauch, M R ^a   Liebig, T ^a   Shimabukuro Vornhagen, A ^a   Kochanek, M ^a   Draube, A ^a   Von Bergwelt Baildon, M S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antigen presenting cells; CD40 activated B cells; Tumour immunothrapy

Indexed keywords

CD40 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; L SELECTIN; RITUXIMAB;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY CANCER; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 58149312923     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03820.x     Document Type: Article

References (56)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 10 : 909 15.
2. Luft T, Jefford M, Luetjens P et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002 100 : 1362 72.
3. Kuroda E, Sugiura T, Okada K, Zeki K, Yamashita U. Prostaglandin E2 up-regulates macrophage-derived chemokine production but suppresses IFN-inducible protein-10 production by APC. J Immunol 2001 166 : 1650 8.
4. von Bergwelt-Baildon M, Popov A, Saric T et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006 108 : 228 37.
5. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997 159 : 28 35.
6. Sharma S, Stolina M, Lin Y et al. IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999 163 : 5020 8.
7. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk A. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002 99 : 2468 76.
8. Sato K, Kawasaki H, Nagayama H et al. TGF-{beta}1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol 2000 164 : 2285 95.
9. Kobie J, Wu R, Kurt R et al. Transforming growth factor {beta} inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003 63 : 1860 4.
10. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996 2 : 1096 103.
11. Dorrie J, Schaft N, Muller I et al. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother 2008 57 : 467 77.
12. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998 161 : 3912 18.
13. Kleindienst P, Brocker T. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo. Immunology 2005 115 : 556 64.
14. Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol 2006 177 : 4481 7.
15. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992 258 : 1156 9.
16. Gilbert KM, Weigle WO. Tolerogenicity of resting and activated B cells. J Exp Med 1994 179 : 249 58.
17. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, Mishra GC. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol 2003 170 : 5897 911.
18. Ritchie DS, Yang J, Hermans IF, Ronchese F. B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. Scand J Immunol 2004 60 : 543 51.
19. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004 103 : 2046 54.
20. Fujiwara H, Melenhorst JJ, El Ouriaghli F et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 2005 11 : 4495 503.
21. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003 63 : 2836 43.
22. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006 107 : 2786 9.
23. Mason NJ, Coughlin CM, Overley B et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 2008 15 : 955 65.
24. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002 99 : 3319 25.
25. Barrou B, Benoit G, Ouldkaci M et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004 53 : 453 60.
26. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007 30 : 116 22.
27. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000 6 : 2175 82.
28. Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001 167 : 7150 6.
29. Gitlitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003 26 : 412 19.
30. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002 109 : 409 17.
31. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002 8 : 3369 76.
32. Lee D. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score < or = 7. Clin Prostate Cancer 2003 2 : 81 3.
33. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000 60 : 829 33.
34. Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002 51 : 637 44.
35. Mu LJ, Kyte JA, Kvalheim G et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005 93 : 749 56.
36. Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 2000 43 : 59 62.
37. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002 25 : 500 8.
38. Perambakam S, Hallmeyer S, Reddy S et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006 55 : 1033 42.
39. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000 18 : 3894 903.
40. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003 63 : 2127 33.
41. Su Z, Dannull J, Yang BK et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005 174 : 3798 807.
42. Thomas-Kaskel AK, Zeiser R, Jochim R et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006 119 : 2428 34.
43. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006 55 : 1524 33.
44. Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006 66 : 5910 18.
45. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004 10 : 475 80.
46. Wiesner M, Zentz C, Mayr C et al. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 2008 3.
47. Yamashita Y, Tsurumi T, Mori N, Kiyono T. Immortalization of Epstein-Barr virus-negative human B lymphocytes with minimal chromosomal instability. Path Int 2006 56 : 659 67.
48. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006 6 : 836 48.
49. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006 12 : 2326s 30s.
50. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008 371 : 771 83.
51. Popov A, Schultze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med 2008 86 : 145 60.
52. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006 108 : 1435 40.
53. Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002 169 : 2164 71.
54. Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997 100 : 2757 65.
55. von Bergwelt-Baildon MS, Schultze JL, Nadler LM. CD40-activated B-cells as antigen presenting cells: from immunobiology to immunotherapy. Modern Aspects Immunobiol 2003 3 : 71 4.
56. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 16 : 2825 33.